Japan's First CRO CMIC On How ICH Affects Clinical Trials in Japan: An Interview with PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
Established in 1992 as the first contract clinical trial research organization in Japan, CMIC is now one of the largest Japanese CROs and currently employs more than 2,500 employees. The company has several business segments including clinical trials, and contract manufacturing and sales, and operates in Japan, the United States, South Korea, Taiwan, Singapore, and China. CMIC's CRO business accounted for 58 percent of its sales. CMIC Corporate Officer Asia Development Moriaki Akasaki sat down with PharmAsia News Japan bureauto give his perspectives on clinical trials in Japan and other Asian countries under the influence of the International Conference on Harmonization.
You may also be interested in...
Japan's First CRO CMIC On How ICH Affects Clinical Trials in Japan: An Interview with PharmAsia News (Part 2 of 2)
Established in 1992 as the first contract clinical trial research organization in Japan, CMIC is now one of the largest Japanese CROs and currently employs more than 2,500 employees. The company operates in Japan, the United States, South Korea, Taiwan, Singapore and China. CMIC Corporate Officer Asia Development Moriaki Akasaki sat down with PharmAsia News' Japan bureau to give his perspective on the how the International Conference on Harmonization Good Clinical Practices agreements will affect Japan and other Asian countries. Japan, for the first time is beginning to accept clinical data from China and Koreain accordance with the ICH Regional Harmonization Initiative.
Japan's First CRO CMIC On How ICH Affects Clinical Trials in Japan: An Interview with PharmAsia News (Part 2 of 2)
Established in 1992 as the first contract clinical trial research organization in Japan, CMIC is now one of the largest Japanese CROs and currently employs more than 2,500 employees. The company operates in Japan, the United States, South Korea, Taiwan, Singapore and China. CMIC Corporate Officer Asia Development Moriaki Akasaki sat down with PharmAsia News' Japan bureau to give his perspective on the how the International Conference on Harmonization Good Clinical Practices agreements will affect Japan and other Asian countries. Japan, for the first time is beginning to accept clinical data from China and Koreain accordance with the ICH Regional Harmonization Initiative.
More Than Half Of Trials Conducted In South Korea Led By Pfizer
SEOUL - The number of clinical trials Pfizer Korea conducted in South Korea last year rose sharply to 93 cases from 75 cases in 2007, a result of Pfizer's move to conduct more of its clinical trials in South Korea